B. Wolf

发表

Caspase-3 Is the Primary Activator of Apoptotic DNA Fragmentation via DNA Fragmentation Factor-45/Inhibitor of Caspase-activated DNase Inactivation*

D. Green, F. Echeverri, B. Wolf, 1999, The Journal of Biological Chemistry.

Synthesis and structure-activity relationship of N-acyl-Gly-, N-acyl-Sar- and N-blocked-boroPro inhibitors of FAP, DPP4, and POP.

D. Sutherlin, C. Wiesmann, M. Mayeda, 2007, Bioorganic & medicinal chemistry letters.

Selective Inhibition of Fibroblast Activation Protein Protease Based on Dipeptide Substrate Specificity*

D. Sutherlin, W. Fairbrother, J. M. Elliott, 2006, Journal of Biological Chemistry.

Regulation of plasmin, miniplasmin, and streptokinase-plasmin complex by α2-antiplasmin, α2-macroglobulin, and antithrombin III in the presence of heparin1

S. L. Gonias, B. Wolf, P. K. Anonick, 1990 .

Yersinia virulence factor YopJ acts as a deubiquitinase to inhibit NF-κB activation

Honglin Zhou, V. Dixit, I. Wertz, 2005, The Journal of experimental medicine.

Proteolytically active streptococcal pyrogenic exotoxin B cleaves monocytic cell urokinase receptor and releases an active fragment of the receptor from the cell surface.

J. Musser, S. L. Gonias, V. Kapur, 1994, The Journal of biological chemistry.

Regulation of plasmin, miniplasmin, and streptokinase-plasmin complex by alpha 2-antiplasmin, alpha 2-macroglobulin, and antithrombin III in the presence of heparin.

B. Wolf, P. K. Anonick, S. Gonias, 1990, Thrombosis research.

Apoptosis: Letting Slip The Dogs Of War

D. Green, B. Wolf, 2002, Current Biology.

Rapid Regulation of Macrophage a2-Macroglobulin Receptor/Low Density Lipoprotein Receptor-related Protein by Lipopolysaccharide and Interferon-y

S. L. Gonias, E. Kittler, J. LaMarre, 2022 .

Defective Cytochrome c-dependent Caspase Activation in Ovarian Cancer Cell Lines due to Diminished or Absent Apoptotic Protease Activating Factor-1 Activity*

G. Mills, D. Green, M. Schuler, 2001, The Journal of Biological Chemistry.

Granzyme B-mediated Apoptosis Proceeds Predominantly through a Bcl-2-inhibitable Mitochondrial Pathway* 210

T. Kuwana, D. Green, D. Newmeyer, 2001, The Journal of Biological Chemistry.

Classification of alpha 2-macroglobulin-cytokine interactions based on affinity of noncovalent association in solution under apparent equilibrium conditions.

S. L. Gonias, D. Webb, B. Wolf, 1994, The Journal of biological chemistry.

Epidermal growth factor‐binding protein activates soluble and receptor‐bound single chain urokinase‐type plasminogen activator

B. Wolf, Morry D. Brown, Morry D. Brown, 1995, FEBS letters.

Calpain functions in a caspase-independent manner to promote apoptosis-like events during platelet activation.

D. Green, G. Salvesen, H. Stennicke, 1999, Blood.

Regulation of macrophage alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein by lipopolysaccharide and interferon-gamma.

P. Quesenberry, S. L. Gonias, E. Kittler, 1993, The Journal of clinical investigation.

Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome

Dick D. Mosser, Richard I. Morimoto, Pankaj Tailor, 2000, Nature Cell Biology.

Ordering the Cytochrome c–initiated Caspase Cascade: Hierarchical Activation of Caspases-2, -3, -6, -7, -8, and -10 in a Caspase-9–dependent Manner

Emad S. Alnemri, Seamus J. Martin, D. Green, 1999, The Journal of cell biology.

Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.

S. Ou, C. Lengauer, Wei Hu, 2018, Cancer discovery.

Suicidal Tendencies: Apoptotic Cell Death by Caspase Family Proteinases*

D. Green, Douglas R. Green, Beni B. Wolf, 1999, The Journal of Biological Chemistry.

Distinct Caspase Cascades Are Initiated in Receptor-mediated and Chemical-induced Apoptosis*

M MacFarlane, G M Cohen, D. Green, 1999, The Journal of Biological Chemistry.

Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion.

S. Digumarthy, A. Iafrate, M. Mino‐Kenudson, 2018, Cancer discovery.

Pro-caspase-3 Is a Major Physiologic Target of Caspase-8*

J C Reed, D. Green, L. Ellerby, 1998, The Journal of Biological Chemistry.

Bcl-xL does not inhibit the function of Apaf-1

D. Green, D. Newmeyer, E. Bossy‐Wetzel, 2000, Cell Death and Differentiation.

Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic

U. Nielsen, J. Fitzgerald, O. Burenkova, 2015, Molecular Cancer Therapeutics.

α2‐Macroglobulin and the α2‐Macroglobulin Receptor/LRP A Growth Regulatory Axis a

H. Moses, J. LaMarre, B. Wolf, 1994 .

Characterization and immunohistochemical localization of alpha 2-macroglobulin receptor (low-density lipoprotein receptor-related protein) in human brain.

S. Vandenberg, M. Lopes, B. Wolf, 1992, The American journal of pathology.

A precision therapy against cancers driven by KIT/PDGFRA mutations

A. Gardino, N. Lydon, M. Heinrich, 2017, Science Translational Medicine.

Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial.

Robin L. Jones, O. Mir, W. Tap, 2020, The Lancet. Oncology.

Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.

Yoon-Koo Kang, K. Hoeflich, C. Lengauer, 2019, Cancer discovery.

First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant Fibroblast Growth Factor 19 Signaling as a Driver Event in Hepatocellular Carcinoma.

Nicolas Stransky, V. Mazzaferro, J. Llovet, 2019, Cancer discovery.

Reaction of nerve growth factor gamma and 7S nerve growth factor complex with human and murine alpha 2-macroglobulin.

B. Wolf, J. Vasudevan, S. Gonias, 1993, Biochemistry.

MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations

A. Bardelli, L. Trusolino, A. Bertotti, 2016, Science Translational Medicine.

Neurotrophin binding to human alpha 2-macroglobulin under apparent equilibrium conditions.

B. Wolf, S. Gonias, 1994, Biochemistry.

Clinical Activity in a Phase 1 Study of Blu-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis (AdvSM)

S. Verstovsek, M. Deininger, D. DeAngelo, 2017 .

Preliminary Safety and Clinical Activity in a Phase 1 Study of Blu-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis (SM)

S. Verstovsek, M. Deininger, D. DeAngelo, 2016 .

Targeting kinases with precision

A. Gardino, C. Lengauer, N. Brooijmans, 2018, Molecular & cellular oncology.

Safety, pharmacology, and preliminary clinical activity of MM-151: An oligocolnal anti-EGFR theraputic in patients with cetuximab-resistant CRC and other refractory solid tumors.

M. Beeram, A. Adjei, B. Wolf, 2015 .

Abstract CT043: Highly potent and selective RET inhibitor, BLU-667, achieves proof of concept in a phase I study of advanced,RET-altered solid tumors

S. Ou, M. Brose, V. Subbiah, 2018, Clinical Trials.

First-in-human study of BLU-554, a potent, highly-selective FGFR4 inhibitor designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation

J. Llovet, S. Choo, T. Meyer, 2016 .

Ala657 and conserved active site residues promote fibroblast activation protein endopeptidase activity via distinct mechanisms of transition state stabilization.

C. Wiesmann, M. Mayeda, C. Quan, 2007, Biochemistry.

Peptide substrate profiling defines fibroblast activation protein as an endopeptidase of strict Gly2‐Pro1‐cleaving specificity

W. Fairbrother, C. Wiesmann, Victoria C. Pham, 2006, FEBS letters.

RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations.

D. Bergstrom, D. Shaw, A. Schram, 2023, Cancer discovery.

First-in-human study of highly selective FGFR2 inhibitor, RLY-4008, in patients with intrahepatic cholangiocarcinoma and other advanced solid tumors.

M. Borad, A. El-Khoueiry, A. Schram, 2021 .

Clinical activity of BLU-285 in advanced gastrointestinal stromal tumor (GIST).

Robin L. Jones, O. Mir, M. Heinrich, 2017 .

Nerve growth factor-gamma activates soluble and receptor-bound single chain urokinase-type plasminogen activator.

J. Henkin, B. Wolf, J. Vasudevan, 1993, The Journal of biological chemistry.

Calpain functions in a caspase-independent manner to promote apoptosis-like events during platelet activation.

D. Green, G. Salvesen, H. Stennicke, 1999, Blood.

Phase I Study of Lorvotuzumab Mertansine (LM, IMGN901) in Combination with Lenalidomide (Len) and Dexamethasone (Dex) in Patients with CD56-Positive Relapsed or Relapsed/Refractory Multiple Myeloma (MM)

A. Chanan-Khan, F. Hernandez-Ilizaliturri, C. N. Carrigan, 2012 .

Preliminary safety and activity in a first-in-human phase 1 study of BLU-285, a potent, highly-selective inhibitor of KIT and PDGFRα activation loop mutants in advanced gastrointestinal stromal tumor (GIST)

Robin L. Jones, O. Mir, M. Heinrich, 2016 .

Proteolytic activation of single-chain precursor macrophage-stimulating protein by nerve growth factor-gamma and epidermal growth factor-binding protein, members of the kallikrein family.

E. Leonard, M. H. Wang, T. Yoshimura, 1994, The Journal of biological chemistry.

On the edge of validation--cancer protease fibroblast activation protein.

D. Sutherlin, C. Wiesmann, C. Quan, 2008, Mini reviews in medicinal chemistry.

Yersinia virulence factor YopJ acts as a deubiquitinase to inhibit NF-κB activation

Honglin Zhou, V. Dixit, I. Wertz, 2005, The Journal of experimental medicine.